We see protein-protein interactions directly. Our technology makes it possible to scan all the signal pathways that cancer cell uses.


Our technology lies in the convergence of physics, biology, and electronics. We use the recently developed single-molecule pull-down and co-immunoprecipitation(co-IP) methods to capture the interaction of target protein and probe protein within the excitation volume (protein-protein interactions, “PPI”). We found that PPI metrics of the HER-family receptors are tightly correlated with the drug responses of cancers and ascertained the exceptional predictive power of PPI count for a HER-family receptor-targeted therapy responses.

“Measuring KRAS PPI profiles in combination with EGFR and other growth factors from tumor tissues could be used as a powerful predictive biomarker for the determination of better treatment options.”


“The use of single-molecule PPIs for multiple growth-factor receptors and signaling proteins from individual cancers can also provide strong functional proteomics data to complement next generation sequencing of tumor cells. The combination of these technologies could be instrumental in building more genomics-based and proteomics-based profiles for individual cancer patients, allowing for the application of more specific treatment options: the genomics data would provide information on the mutational status of genes, and the proteomics data would predict which proteins are in an active state and are potentially responsive to different inhibitors.”


“The method, (…) may help guide therapeutic decision-making for the treatment of cancers with no actionable genomic mutations.”


“It provides a bridge between functional proteomics and PPI profiling in cancer cells and tumor tissues, thus presenting an opportunity to improve clinical decision-making for scientists and clinicians in the context of personalized medicine.”

*From Saraon, Punit. et al. Nat. Biomed. Eng.